COVID-19 vaccine, “COVIFENZ® ” (MT-2766) has been approved in Canada

February 24, 2022

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President: Hiroaki Ueno), an operating company of Mitsubishi Chemical Holdings Corporation (Head Office: Tokyo; President: Jean-Marc Gilson) announced that Health Canada has granted full approval for COVIFENZ^® (COVID-19 vaccine, plant-based virus-like particles [VLP], project code: MT-2766) on February 24.

Mitsubishi Tanabe Pharma　Press Release
https://www.mt-pharma.co.jp/e/news/assets/pdf/e_MTPC220224.pdf